Skip to main content
Equibles

MARSHALL WACE, LLP

Position in MLTX — MoonLake Immunotherapeutics

CIK 1318757 LONDON, X0
Back to MLTX Full portfolio

Position in MLTX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$10,715,333
+$8,640,124 QoQ
Shares Held
550,351
+394.3% QoQ
Ownership
0.647%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#28
of 172 holders
Holding Since
Dec 2021
13 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in MLTX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. MLTX ranks #66 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 543,897 $270,169,956
2 INCY
Incyte Corp
 1,310,154 $148,519,056
3 RPRX
Royalty Pharma plc
 2,450,669 $137,409,009
4 SYRE
Spyre Therapeutics, Inc.
 991,693 $88,042,503
5 ALNY
Alnylam Pharmaceuticals, Inc.
 259,799 $78,207,292
6 TVTX
Travere Therapeutics, Inc.
 1,333,207 $75,739,488
7 MANE
Veradermics, Inc
 585,560 $71,988,746
8 DFTX
Definium Therapeutics, Inc.
 1,298,946 $61,102,419

All Filings in MLTX

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $10,715,333 550,351
2026-03-31 $2,075,209 111,331
2025-09-30 $2,302,351 321,109
2025-06-30 $24,978,758 529,211
2025-03-31 $25,040,626 640,917
2024-12-31 $67,432,940 1,245,299
2024-09-30 $58,204,091 1,154,385
2024-06-30 $48,306,761 1,098,630
2024-03-31 $25,664,817 510,946
2023-09-30 $1,735,707 30,451
2023-06-30 $2,977,533 58,383
2022-03-31 $7,257,979 653,872